![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach: Dokumententyp |
Veröffentlichungsdatum
Anzahl der Publikationen: 3
2019
Toth, Bettina; Baston-Buest, Dunja Maria; Behre, Hermann M.; Bielfeld, Alexandra; Bohlmann, Michael; Buehling, Kai; Dittrich, Ralf; Goeckenjan, Maren; Hancke, Katharina; Kliesch, Sabine; Koehn, Frank-Michael; Kruessel, Jan; Kuon, Ruben; Liebenthron, Jana; Nawroth, Frank; Nordhoff, Verena; Pinggera, Germar-Michael; Rogenhofer, Nina; Rudnik-Schöneborn, Sabine; Schuppe, Hans-Christian; Schuering, Andreas; Seifert-Klauss, Vanadin; Strowitzki, Thomas; Tuettelmann, Frank; Vomstein, Kilian; Wildt, Ludwig; Wischmann, Tewes; Wunder, Dorothea und Zschocke, Johannes
(2019):
Diagnosis and Therapy Before Assisted Reproductive Treatments. Guideline of the DGGG, OEGGG and SGGG (S2k Level, AWMF Register Number 015-085, February 2019) - Part 1, Basic Assessment of the Woman.
In: Geburtshilfe und Frauenheilkunde, Bd. 79, Nr. 12: S. 1278-1291
Toth, Bettina; Baston-Buest, Dunja Maria; Behre, HermannM.; Bielfeld, Alexandra; Bohlmann, Michael; Buehling, Kai; Dittrich, Ralf; Goeckenjan, Maren; Hancke, Katharina; Kliesch, Sabine; Koehn, Frank-Michael; Kruessel, Jan; Kuon, Ruben; Liebenthron, Jana; Nawroth, Frank; Nordhoff, Verena; Pinggera, Germar-Michael; Rogenhofer, Nina; Rudnik-Schöneborn, Sabine; Schuppe, Hans-Christian; Schuering, Andreas; Seifert-Klauss, Vanadin; Strowitzki, Thomas; Tuettelmann, Frank; Vomstein, Kilian; Wildt, Ludwig; Wischmann, Tewes; Wunder, Dorothea und Zschocke, Johannes
(2019):
Diagnosis and Treatment Before Assisted Reproductive Treatments. Guideline of the DGGG, OEGGG and SGGG (S2k Level, AWMF Register Number 015-085, February 2019) - Part 2, Hemostaseology, Andrology, Genetics and History of Malignant Disease.
In: Geburtshilfe und Frauenheilkunde, Bd. 79, Nr. 12: S. 1293-1307
2018
Cheney, Catherine P.; Thorand, Barbara; Huth, Cornelia; Berger, Katja; Peters, Annette; Seifert-Klauss, Vanadin; Kiechle, Marion; Strauch, Konstantin und Quante, Anne S.
(2018):
The Association between Serum 25-Hydroxyvitamin D and Cancer Risk: Results from the Prospective KORA F4 Study.
In: Oncology Research and Treatment, Bd. 41, Nr. 3: S. 117-121